SER Serina: Multiplikator Forward P/S

Serina Therapeutics - logo grafis emiten SER

Serina Therapeutics, Inc. (SER) develops polymer delivery systems for Parkinson's disease medications, ensuring stable demand and long-term margins. The organization's forward P/S ratio visualizes market value relative to expected revenues, with the metric settling at 311.20. Patents for drug transport methods block access for smaller players, although the lack of current sales and the clinical trial stage deprive the company of pricing power.

SER (Serina Therapeutics) riwayat Rasio kapitalisasi pasar marang pendapatan mangsa ngarep saka 28.03.2024 nganti 17.11.2026

SER (serinatherapeutics.com): rincian analitis lan laporan miturut indikator

Ringkesan analisis perusahaan:Serina Pharma SER
Sampel barang Serina Therapeutics, Inc.

The development of the POZ platform for Parkinson's disease therapy transitions Serina Therapeutics, Inc. (SER) into an active growth phase, where market value is assessed through future revenue streams. The forward P/S trajectory reflects expectations regarding business model viability and debt load, allowing investors to balance the potential for scaling innovations against the risk of capital freeze in highly leveraged assets.